Todos os estudos
ConcluídoFase IIntervencionista

A study of a new vaccine against the MERS virus in adults aged 50 to 70 years

Middle East Respiratory Syndrome (MERS) is a severe viral chest infection that can cause serious pneumonia. There is currently no approved vaccine or cure. Scientists at the University of Oxford have created a new MERS vaccine using the same proven technology behind their COVID-19 vaccine. This early-stage trial is looking at how safe the vaccine is and how the immune system responds in adults aged 50 to 70. Researchers also want to find out if having had the Oxford/AstraZeneca COVID-19 jab in the past makes any difference to how well this new jab works. Volunteers will receive two injections given 12 weeks apart. Most will get the trial vaccine, while a small group will get a dummy saltwater injection (placebo). Everyone is closely monitored for one year. Taking part will not give you MERS, but it helps doctors prepare for future virus outbreaks.

Em resumo

Status
Concluído
Fase
Fase I
Patrocinador
Universidade de Oxford
Meta de inscrição
84
Iniciar
18 Abr 2023
Conclusão estimada
31 de janeiro de 2024

Sobre o que é este estudo?

Middle East Respiratory Syndrome, often called MERS, is an illness caused by a coronavirus. First discovered in 2012, it can lead to severe breathing problems, fever, pneumonia, and even death. While MERS cases are rare and mostly found in the Middle East, health experts view it as a serious threat because there are currently no licensed vaccines or specific treatments available to protect against it.

To help solve this, researchers at the University of Oxford have developed a new vaccine called ChAdOx1 MERS. It uses the exact same harmless carrier technology as the widely used Oxford/AstraZeneca COVID-19 vaccine. Earlier small studies showed encouraging results in younger adults aged 18 to 50. This new trial is taking the next step by testing the vaccine in people aged 50 to 70, whose immune systems may respond differently.

Another key goal is understanding how our immune 'memory' works. Because so many people in the UK had the Oxford/AstraZeneca COVID-19 vaccine, researchers want to see whether having had that jab in the past affects how well your body responds to another vaccine built on the same framework. The findings will help protect communities against MERS and guide the design of future vaccines for other emerging viruses.

Pontos principais

  • This trial is testing a new Oxford-developed vaccine against MERS in adults aged 50 to 70.
  • MERS is a serious respiratory illness with no current approved vaccine or cure.
  • Participants receive two injections, 12 weeks apart, and are monitored for one year.
  • Five out of six volunteers receive the study vaccine, while one receives a saltwater placebo.
  • The trial will help show if prior Oxford/AstraZeneca COVID jabs change how the body responds to new vaccines.

Quem pode ser elegível?

This study is looking for volunteers aged between 50 and 70 who are in generally good health. Having a stable, long-term health condition is usually fine, as long as your treatment has not changed and you have not needed to go to hospital for it in the last three months.

The trial is split into two groups. One group is for people who have previously had at least two doses of the Oxford/AstraZeneca COVID-19 vaccine. The other group is for people who have never had this specific type of vaccine before.

To take part, you must be willing to attend regular clinic visits, use an electronic diary on a smartphone or computer, and agree not to donate blood during the study year. Women who could become pregnant must have a negative pregnancy test and agree to use effective contraception, as the effects on unborn babies are not yet known. Pregnant or breastfeeding women cannot take part.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. I am between 50 and 70 years of age.
  2. My current health is stable, with no hospital visits or major treatment changes in the last 3 months.
  3. I have regular access to the internet to complete an online symptom diary.
  4. I am willing to pause donating blood for the 12-month study period.
  5. If applicable, I am not pregnant or breastfeeding, and I am willing to use reliable contraception.
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

Taking part begins with an online health form, followed by a telephone call and a health check at the clinic. If you join, you will be in the study for about one year. You will receive two injections in your upper arm, given 12 weeks apart. Out of every six participants, five will receive the trial vaccine and one will receive a dummy saltwater jab (placebo). Neither you nor the study team will know which one you received until the trial finishes.

After each injection, you will wait at the clinic for 30 minutes so nurses can check on you. You will be given an oral thermometer and access to an online diary to record any symptoms for the first few weeks. Over the course of the year, you will attend follow-up clinic visits for routine health checks and small blood samples so scientists can measure your immune response. You will also have access to a 24-hour phone line to reach a study doctor at any time.

Riscos e benefícios potenciais

You are unlikely to get any direct health benefit from taking part, as MERS is not currently circulating in the UK, and this trial cannot guarantee protection against future infection. However, your involvement could help protect people worldwide in future outbreaks. The vaccine cannot give you MERS because it contains no live virus. Common side effects are usually mild and fade in a few days, such as arm soreness, tiredness, headache, or mild feverish chills. As with any early-stage medicine, unexpected side effects are possible, though severe reactions are very rare. Taking part is entirely voluntary, and you are free to leave the study at any time without giving a reason.

Localizações (2)

  • Liverpool Vaccine Group
    Apenas cidade
    Liverpool, England
  • Oxford Vaccine Group
    Aproximado
    Oxford, England

Perguntas frequentes

Can I catch MERS from the trial vaccine?

No. The vaccine does not contain any live MERS virus, so it is impossible to catch MERS from taking part in the trial.

Will I definitely get the new MERS vaccine?

Not necessarily. For every six people who join, five receive the trial vaccine and one receives a harmless saltwater injection (placebo). A computer chooses this at random.

Will this vaccine protect me from COVID-19?

No. Although this vaccine uses similar technology to the Oxford/AstraZeneca COVID-19 jab, it is designed specifically for the MERS virus and will not protect you against COVID-19.

What side effects might I feel after the jab?

Most people only notice mild reactions such as pain or redness where the needle went in, a mild headache, feeling tired, or slight muscle aches that clear up within two to three days.

What happens if I change my mind after joining?

You are free to leave the trial at any point. Your decision will not affect your normal medical care or your relationship with your GP.

Como saber mais

Maheshi Ramasamy

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.